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Hepatitis E virus (HEV), an enterically transmitted pathogen, is one of the major causes of acute hepatitis in humans worldwide,
being responsible for outbreaks and epidemics in regions with suboptimal sanitary conditions, in many of which it is endemic.
In industrialized countries, hepatitis E is rarely reported, but recent studies have revealed quite high human seroprevalence rates
and the possibility of porcine zoonotic transmission. There is currently no specific therapy or licensed vaccine against HEV in-
fection, and little is known about its intracellular growth cycle, as until very recently no efficient cell culture system has been
available. In the present study, vaccinia viruses have been used to express recombinant HEVORF2 proteins, allowing the study
of their glycosylation patterns and subcellular localization. Furthermore, the expressed proteins have been shown to be good
antigens for diagnostic purposes and to elicit high and long-lasting specific anti-HEV titers of antibodies in mice that are pas-
sively transferred to the offspring by both transplacental and lactation routes.
Hepatitis E virus (HEV) is a spherical, nonenveloped virusaround 27 to 34 nm in diameter, whose genome is a single-
stranded RNA molecule of positive polarity and approximately
7.2 kb in length, containing 3 open reading frames (ORFs) and a 3=
poly(A) tail (39, 47). ORF2 is synthesized as a large glycoprotein
precursor that is cleaved into the mature viral capsid protein,
which harbors immunoreactive epitopes; therefore, it has largely
been used in diagnostic and vaccine development. ORF2 contains
three potential N-glycosylation sites and a putative signal peptide
at its 3= end (17, 50), and it has been implicated in viral replication,
as it binds to the 5= end of the viral genome (44). Until very re-
cently (42, 43, 48, 49), no efficient HEV-susceptible cell culture
was available; thus, different heterologous expression systems
have been used to studyORF2 glycosylation and intracellular traf-
fic, with disparate results (12, 17, 50, 51).
HEV is classified into four genotypes (gt) that infect humans,
although only gt3 and gt4 have been isolated in other animal spe-
cies, mainly pigs (2, 6, 29, 36) and, recently, rats (21, 23, 37). HEV
is enterically transmitted and causes epidemic outbreaks in areas
with inadequate hygienic conditions and/or water supplies, and
thus, it has become an important public health concern. Lately, an
increase in the number of sporadic autochthonous cases has been
reported in industrialized countries, and its zoonotic potential has
been documented (7, 35).
The course of hepatitis E disease is variable, including icteric
and anicteric hepatitis, and severe hepatitis with development of
fulminate hepatic failure (FHF), but it can also be asymptomatic
(25) or become chronic in immunosuppressed and organ trans-
plant patients (6, 22). Although still controversial (30), HEVmay
cause substantial morbidity and mortality in pregnant women,
with mortality rates of up to 25% due to FHF, which may lead to
spontaneous abortion and stillbirths (33).
Since viremia is usually limited to the acute phase of the infec-
tion, the diagnosis of the disease is mainly dependent on serology.
Currently, commercially available kits are designed to detect anti-
HEV in humans and include short fragments of ORF2 and ORF3
of gt1 and gt2, but not of gt3 or gt4, the most prevalent in indus-
trialized countries in swine and humans (31). However, various
reports indicate that commercial assays sometimes failed to detect
specific antibodies in sera from patients with proven HEV gt3
infections, and thus, the number of autochthonous HEV infec-
tions in industrialized regions may have been underestimated (2,
3, 8, 14, 20, 28).
No specific treatment of HEV infection or approved vaccine is
yet available, although due to the lack of an efficient cell culture
system, several recombinant proteins and peptides have been as-
sayed (1), with two already in clinical trials (41, 52, 53).
In the present study, the glycosylation and intracellular trans-
port of vaccinia virus-expressed HEV ORF2 proteins have been
analyzed in mammalian cells, and their antigenic and immuno-
genic capabilities have been further evaluated.
MATERIALS AND METHODS
Generation of vaccinia viruses expressing recombinant ORF2 proteins
of HEV gt3. Amplification and cloning of the complete HEV gt3 ORF2
(GenBank accession number JQ522948) and a truncated (1-111)-ORF2
fragment of it into TOPO-TA plasmid (Invitrogen, Carlsbad, CA) using
specific primers (sequence available upon request) were performed as
previously described (19). Then, genes were transferred to pRB21-Myc-
His, which includes aMyc epitope followed by a tail of 6His residues at the
C termini of the proteins, to yield plasmids pRB21-ORF2-Myc-His and
pRB21-(1-111)-ORF2-Myc-His, respectively. These plasmids were used
to generate the corresponding recombinant vaccinia viruses, rVV-ORF2
and rVV-(1-111)-ORF2, which were further purified through a sucrose
Received 8 March 2012 Accepted 9 May 2012
Published ahead of print 16 May 2012
Address correspondence to Juan-Carlos Saiz, jcsaiz@inia.es.
* Present address: Nereida Jiménez de Oya, Division of Immunology,
Transplantation and Infectious Diseases, SRSI, Milan, Italy; Miguel A. Martín-
Acebes, Centro de Biología Molecular Severo Ochoa (CSIC-UAM), Consejo
Superior de Investigaciones Científicas (CSIC), Campus de Cantoblanco, Madrid,
Spain.
Copyright © 2012, American Society for Microbiology. All Rights Reserved.
doi:10.1128/JVI.00610-12
7880 jvi.asm.org Journal of Virology p. 7880–7886 August 2012 Volume 86 Number 15
cushion (4). The Western Reserve (WR) strain of vaccinia virus, grown
and purified under the same conditions, was used as the control virus.
Protein expression and characterization.Monolayers of BHK-21 or
BSC-1 cells were infected with recombinant vaccinia viruses orWR (mul-
tiplicity of infection [MOI]  1 PFU/cell). When cytopathic effect was
complete, cells were collected and centrifuged at 210  g for 5 min. The
pellet was resuspended in lysis buffer (1%Nonidet P-40, 50mMTris-HCl
[pH 7.6], 150 mM NaCl, 2 mM EDTA) supplemented with complete
protease inhibitor cocktail (Roche, Mannheim, Germany) for 30 min at
4°C, vortexed for 5 min, sonicated 3 times for 10 s each time, and centri-
fuged at 15,680 g for 2 min. The supernatant was recovered and kept at
20°C until use. Protein expression was analyzed by Western blotting
(WB) (19, 20).
Glycosylation of the recombinant HEV proteins was analyzed upon
infection (MOI  2) of BHK-21 cells. One microgram/microliter of tu-
nicamycin (Sigma, St. Louis,MO), an inhibitor ofN-glycosylation (9, 46),
was added after viral adsorption (0 h postinfection [h p.i.]) or 4 h p.i. As a
positive control, N-glycosylation of the later-expressed B5 vaccinia virus
protein (10) was analyzed in WR-infected cells. Brefeldin A (BFA)
(Sigma), an inhibitor of the transport between the Golgi and the endo-
plasmic reticulum (ER) (24), was also included in the assays at a final
concentration of 5 g/ml in dimethyl sulfoxide (DMSO). As a control,
cells were similarly treated with equal amounts of the drug solvents.
Protein extracts were tested as enzyme-linked immunosorbent assay
(ELISA) antigens. Microplates (Polysorp; Nunc, Roskilde, Denmark)
were coated with 50 l/well of serial dilutions of proteins extracts in 50
mM carbonate-bicarbonate buffer (pH 9.6), and the ELISA was per-
formed as described previously (19, 20).
Antibodies, staining, and reagents. Recombinant proteins were de-
tected using an anti-C-Myc mouse monoclonal antibody (Roche), an an-
tihistidine mouse monoclonal antibody (Clontech Laboratories, Inc.,
Mountain View, CA), or 4G11, an anti-r(1-111)-ORF2 mouse monoclo-
nal antibody (available upon request), conjugated to Alexa Fluor 488 (AF-
488). Wheat germ agglutinin (WGA; Invitrogen), a lectin that labels spe-
cifically the Golgi complex (34), conjugated with AF-594 was used to
reveal the position of the Golgi complex. Likewise, as specific markers of
the ER, an anticalnexin rabbit polyclonal antibody (Stressgen, MI) or an
anticalreticulin rabbit polyclonal antibody (Abcam, Cambridge, United
Kingdom) was used. To analyze the localization of vaccinia virus proteins
to the cell surface, a rat monoclonal antibody that recognizes the B5 vac-
cinia virus protein expressed in the extracellular surface of vaccinia virus-
infected cells (40) was used. Secondary antibodies against mouse, rabbit,
or rat anti-IgG coupled to AF-488 or AF-594 were purchased from Invit-
rogen.
Immunofluorescence and confocal microscopy. Cell monolayers
were grown on glass coverslips (Menzel-Glaser, Braunschweig, Ger-
many), infectedwith the tested recombinant vaccinia viruses at anMOI of
1 PFU/cell, and processed, 7 or 17 h p.i. as described previously (27).
Depending on the experiment, cells were fixed in 4% paraformaldehyde
(PFA) or in cold absolute methanol. In some instances, PFA-fixed cells
were permeabilized before processing (27). All cells were further incu-
bated with phosphate-buffered saline (PBS)-0.1 M glycine and primary
and fluorescently labeled secondary antibodies and then mounted with
Fluoromount-G (SouthernBiotech, Birmingham,AL). Preparationswere
observed with a Leica TCS SPE confocal laser scanning microscope using
an HCX PL APO 63/1.4 oil immersion objective. Images were acquired
using Leica advanced fluorescence software (LAS AF). Optical slice thick-
ness for all confocal images displayed was 1 Airy unit.
Animals and vaccination schedule. Groups (6 to 9) of 8-week-old
Swiss outbredmice were inoculated intraperitoneally (i.p.), three times at
a 2-week intervals, with sucrose cushion-purified recombinant vaccinia
viruses orWR. For each recombinant virus, mice were inoculated with an
initial dose of either 105 or 106 PFU/mouse, followed by two additional
doses of 104 or 105 PFU/mouse. Blood samples were collected from the
jaw vein (maxillary sinus) previously to the first inoculation and 21, 41,
and 119 days later. Throughout the experiments, animals were given
food and water ad libitum and monitored daily. Experiments were ap-
proved and performed according to the guidelines for animal experimen-
tation of the animal safety committee of our institution.
To analyze vertical transmission of acquired immunity from vac-
cinated mothers to their offspring, two additional groups of 4 female
mice were inoculated under the same schedule with the highest doses
of virus as described previously (18) and crossed after the third inoc-
ulation. In parallel, 8 unvaccinated female black-furred B6D2 mice
were also crossed. At delivery, half of the pups born to vaccinated
mothers were interchanged with half of the pups born to their assigned
control unvaccinated B6D2 mothers. In this way, vaccinated and non-
vaccinated mothers nursed some of their own pups and some fostered
ones. To avoid the interference of colostrum, some pups born to non-
vaccinated mothers were transferred to vaccinated mothers 9 days
postpartum. Pups (4 to 10) from the different groups were anesthe-
tized, bled, and sacrificed at different times (3, 9, 18, and 30 days
postdelivery). To analyze intrauterine transmission, cesarean sections
were performed in two additional vaccinated mice. Antibodies raised
in mice were tested by an ELISA based on r(1-111)-ORF2 HEV protein
partially purified from insect larvae as previously described (20).
RESULTS
Expression of HEV gt3 rORF2 proteins inmammalian cells and
glycosylation analysis. Western blot analyses of extracts from
mammalian cells infected with the recombinant vaccinia viruses
rVV-ORF2 and rVV-(1-111)-ORF2 showed proteins with appar-
ent masses of around 80 to 90 kDa and a doublet of around 60 to
62 kDa, respectively (Fig. 1), although some minor species could
also be detected. The specificity of the bands was confirmed, as
none of them were detected in WR-infected cellular extracts (Fig.
1) or when anti-HEV IgG-negative swine sera were used (data not
shown).
Glycosylation analyses showed that in the presence of tunica-
mycin, an N-glycosylation inhibitor, only the complete rORF2-vv
presented a differentmobility pattern with several isoforms, while
r(1-111)-ORF2-vv mobility pattern was not altered (Fig. 2A and
B). Control of the assay confirmed the inhibitory action of the
tunicamycin, as no glycosylated form of vaccinia virus B5 protein
was detected in its presence (Fig. 2C). Western blot analysis of
rORF2-vv expression after treatment with BFA, a drug that inhib-
its the transport between the Golgi and the ER, showed that al-
though some specific isoforms could be detected only in the ab-
sence of the drug, most of them were not altered by the treatment
(Fig. 2D).
Subcellular location of recombinant proteins inmammalian
cells. Immunofluorescence and confocal microscopy analyses of
BHK-21 or BSC-1 cells infected with recombinant vaccinia virus
showed a reticular pattern for both proteins, with a juxtanuclear
accumulation of rORF2-vv. As displayed in Fig. 3A, the jux-
tanuclear ORF2 signal in rVV-ORF2-infected cells was coincident
with theGolgi complex, and this signalwas absent in rVV-(1-111)-
ORF2-infected cells. Double-labeling experiments with ER-spe-
cific markers anticalnexin and anticalreticulin showed that both
recombinant proteins localized to the ER (Fig. 3B andC). By using
a specific anti-ORF2 monoclonal antibody (4G11) conjugated
with Alexa Fluor 488, it was observed that rORF2-vv, but not
r(1-111)-ORF2, was located in the cell surface. The rORF2-vv la-
beling appeared as a punctate pattern that was not coincident with
mature vaccinia viruses, as revealed by B5 staining (Fig. 3D).
ELISA based on the expressed proteins. The antigenicity of
the expressed HEV recombinant proteins was assessed by ELISA
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after establishing the optimal antigen (1:500 and 1:2,500 for
rORF2-vv and r(1-111)-ORF2-vv, respectively) and serum (1:100)
dilutions by using a battery of previously well-characterized pos-
itive and negative swine sera (20). As a negative control, protein
extracts from WR-infected cells were used. The cutoff the assays
was established as 2-fold the absorbance of the negative control
(0.15; range, 0.05 to 0.14). Comparison of the results obtained
with both recombinant proteins showed a 94.5% (52/55) concor-
dance. Further comparison with two previously validated ELISAs
based on rORF2 proteins expressed in insect larvae (20) showed
89.5% (51/57) and 92.8% (65/70) concordances. These proteins
were obtained upon inoculation of Trichoplusia ni larvae with
recombinant baculoviruses and partially purified in their native
forms bymeans of their His tails (19, 20). Likewise, a concordance
of 76.8% was found between the ELISA based on the vaccinia
virus-expressed truncated r(1-111)-ORF2-vv and a widely used
commercial kit (MP diagnostic kit; Genelabs) modified for use
with swine sera as described previously (20).
To further confirm the accuracy of the assays, all sera with
discordant ELISA results, that is, those that were positive by one of
the assays and negative with the others, and 10 randomly selected
concordant sera were tested by WB as a reference assay (14, 20).
The sensitivity and specificity of the in-house assay for detecting
anti-HEV antibodies were 91.3% and 100%, while those of the
commercial assay were 74% and 87%, respectively.
Inmunogenicity of the expressed proteins. All mice vacci-
nated with rVV-ORF2 presented specific antibodies in sera after
two inoculations (22 days postinoculation [d.p.i.]), regardless of
the viral dose inoculated. In contrast, 3 infections with the highest
dose (106 PFU) were needed to elicit an antibody response in all
rVV-(1-111)-ORF2-vaccinated animals (Table 1). As expected,
antibody levels increased with the number of inoculations (Fig.
4A) and reached high titers through the end of the experiment,
119 d.p.i. (Fig. 4B). Antibody titers were consistently higher in
mice inoculated with rVV-ORF2, in particular at a 105-PFU
dose.
FIG 1 Western blot analysis of recombinant rVV-ORF2 and rVV-(1-111)-ORF2 proteins in BHK-21 mammalian cells. Western blots were stained with a
monoclonal anti-His antibody (A) or anHEV-positive porcine serum (B), as described previously (19, 20). Lane 1, rVV-(1-111)-ORF2-infected cells; lane 2,WR
vaccinia virus-infected cells; lane 3, rVV-ORF2-infected cells. Molecular mass markers are shown on the left. Black and white arrows mark the positions of the
rORF2-vv and r(1-111)-ORF2-vv proteins, respectively.
FIG 2 Western blot analysis of the glycosylation patterns of HEV recombinant rORF2-vv (A and D) and r(1-111)-ORF2-vv (B) proteins and of B5WR vaccinia
virus protein (C) in infected BHK-21 cells. Western blots were stained with a monoclonal anti-His antibody (A, B, and D) or with an anti-B5 rat monoclonal
antibody (C). Infected-cell extracts treated with the drugs at 0 or 4 h p.i. or not treated () were harvested 7 h p.i. and processed as described in Materials and
Methods. Molecular mass markers are shown on the left.
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Vertical transfer of acquired immunity. As shown in Table 2,
all pups (n  73) nursed by mothers vaccinated with any of the
two recombinant vaccinia viruses (rVV-ORF2 or rVV-(1-111)-
ORF2), either their own pups (n  39) or those fostered from
nonvaccinated mothers (n 34), presented specific antibodies in
sera that weremaintained until the end of the experiment (30 days
postpartum [d.p.p.]). Similar results were obtained in those cases
in which colostrum contribution to vertical transmission of the
acquired immunity was avoided (data not shown). On the other
hand, around 80% (n 26) of the pups born to vaccinatedmoth-
ers and nursed by nonvaccinated ones presented specific antibod-
ies in sera at 9 d.p.p., but by day 30 p.p. no specific antibodies were
detected in any of the pups tested (Table 2). All pups (n 18) born
by cesarean section of 2 vaccinatedmothers also presented specific
TABLE 1 Number of mice with specific anti-HEV antibodies at 21 and
41 days after vaccination with different doses of the vaccinia viruses
Inoculated virus Dose (PFU/mouse)
No. of mice with specific
anti-HEV antibodies/
total no. of mice (%)
22 d.p.v.a 41 d.p.v.
rVV-ORF2 105 6/6 (100) 6/6 (100)
106 9/9 (100) 9/9 (100)
rVV-(1-111)-ORF2 10
5 0/6 (0) 4/6 (66.6)
106 4/9 (44.4) 9/9 (100)
WR 106 0/6 (0) 0/6 (0)
a d.p.v., days postvaccination.
FIG 3 Cells infected with HEV recombinant rVV-ORF2, rVV-(1-111)-ORF2, and WR vaccinia virus (MOI  1 PFU/cell) were fixed and processed for
immunofluorescence and confocal microscopy as described in Materials and Methods. Recombinant HEV proteins were detected using anti-C-Myc or
anti-r(1-111)-ORF2 (4G11) mouse monoclonal antibodies. Vaccinia viruses on the cell surface were visualized by staining nonpermeabilized cells with an
anti-B5 rat monoclonal antibody (-B5). Cellular structures were labeled by using specific antibodies: wheat germ agglutinin (WGA) for Golgi and
anticalnexin and anticalreticulin rabbit polyclonal antibodies for ER. Suitable secondary antibodies coupled to AF-488 were used. Scale bar, 25 m.
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antibodies (data not shown). As expected, none of the pups (n
31) born to nonvaccinatedmothers and nursed by thempresented
specific antibodies in sera.
Levels of antibodies transmitted by rVV-ORF2-vaccinated
mothers, transplacentally and/or by nursing, to their offspring
were overall higher than those transmitted by rVV-(1-111)-ORF2-
vaccinated mothers (Fig. 5).
DISCUSSION
Only very recently has HEV-susceptible cell culture been described
(42, 43, 48, 49), and this fact has hampered the study of the viral
growth cycle, including the possible role of ORF2 glycosylation.
Glycosylation frequently affects protein folding and intracellular
transport along the exocytic pathway (13), and although nonenvel-
oped viruses were not considered to have glycosylated protein, there
are well-known exceptions, such as that of rotaviruses (11).
HEVORF2 contains three putative N-glycosylation sites and a
putative signal peptide at its 3= end (17, 51), but reports describing
its glycosylation status using different expression systems are con-
tradictory. Glycosylation ofORF2 at the ER, due to the presence of
a putative signal peptide (51) or of 3 sequons (12, 50), has been
described. This glycosylation status may affect ORF2 intracellular
trafficking, allowing its translocation from the cytosol to the ER
(45). Even more, the presence of mannose-rich residues on ORF2
has been related with a circulation of ORF2 throughout the Golgi
(17). However, a cytoplasmic localization that excluded the ER
has also been reported (12).
In the present study, the two recombinant ORF2 proteins were
expressed at similar levels in mammalian cells with the expected
mass, and while, in accordance with most of the aforementioned
studies, ORF2 was glycosylated, the truncated form was not. This
may be a consequence of the absence of the signal peptide region
on r(1-111)-ORF2-vv, which would hamper its translocation to
the ER and the consequent glycosylation. Immunofluorescence
and confocal microscopy analyses of both recombinant proteins
showed that they localize at the ER, but only rORF2-vv circulates
throughout the Golgi complex. These results are supported by
treatment with BFA, a drug that inhibits the transport between the
ER and Golgi (24), where it was shown that although some glyco-
sylation may occur at the Golgi, it more likely takes place at other
cellular locations. Even more, confirming previous studies (17,
51), our data with permeabilized and nonpermeabilized cells re-
vealed that rORF2-vv could also be observed at the cell surface,
while r(1-111)-ORF2-vv could not. This could be again due either
to an incorrect glycosylation pattern or to the absence of the hy-
drophobic N-terminal motif on r(1-111)-ORF2-vv, which would
impair its association to the membranes. Our data show that
r(1-111)-ORF2-vv presents a uniform localization characteristic
of ER even in the absence of a putative signal peptide. This obser-
TABLE 2 Number of newborn mice with anti-HEV antibodies and route of transmissiona
Mothers Origin of pups (no.)
No. of anti-HEV-positive newborns/total tested (%)
0 d.p.d. 3 d.p.d. 9 d.p.d. 18 d.p.d. 30 d.p.d.
Vaccinated Own, i.u L (39) 12/12 (100) 9/9 (100) 5/5 (100) 6/6 (100) 7/7 (100)
Fostered, L (34) 7/7 (100) 7/7 (100) 9/9 (100) 11/11 (100)
Unvaccinated Own, none (31) 0/4 (0) 0/9 (0) 0/5 (0) 0/9 (0) 0/4 (0)
Fostered, i.u. (26) 7/8 (87.5) 4/5 (80) 2/8 (25) 0/5 (0)
a Mice were tested at different days postdelivery (d.p.d.). i.u, intrauterine; L, lactation.
FIG 4 Anti-HEV IgG levels elicited in mice vaccinated with vaccinia viruses. (A) Anti-HEV IgG antibodies levels raised in mice after two and three inoculations
with either 105 or 106 PFU/mouse of rVV-ORF2 (black bars), rVV-(1-111)-ORF2 (gray bars), or WR (white bars). (B) Levels of anti-HEV IgG antibodies raised
over time by mice vaccinated with 106 PFU/mouse of rVV-ORF2 (black bars), rVV-(1-111)-ORF2 (gray bars), or WR (white bars). ELISAs were conducted as
described previously (20). Results are expressed as the average absorbance (A495) values. Standard deviations are shown by error bars.
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vation suggests that the association of ORF2 with the ER may be
mediated by the hydrophobic region near its C terminus or by
sequences not yet identified. Although our results cannot com-
pletely rule out that both proteins interact with cellular or vaccinia
virus proteins, which may facilitate their transport to the ER, they
are indirectly supported by reports indicating that both proteins
react with the 5= end of HEVRNA (44), and by the ER localization
of the viral replicase (38). Thus, our analysis showed that the com-
plete ORF2 was localized to the ER, to the Golgi, and at the cell sur-
face, confirming the expected trafficking of the protein, while the
truncated formwasmainly observed at the ER. These different intra-
cellular localizationpatternsareunlikelydue toexperimental artifacts
as a consequence of protein overexpression, as previously suggested
(12, 50), since the two proteins were expressed at similar levels.
An early report describing the expression of ORF2 and ORF3
proteins from HEV genotype 1 suggested their putative utility to
analyze the immune response to HEV (5); therefore, once the
glycosylation and subcellular patterns of the expressed proteins
were partially characterized, their antigenicity and immunogenic-
ity were evaluated. Even though commercial assays for detection
of anti-HEV antibodies in humans, which are based on proteins of
gt1 and/or gt2, are available, there are still concerns about their
utility for infections caused by other genotypes (2, 3, 14, 20, 28). In
addition, they are not designed to be used with samples from
swine, a likely natural reservoir of HEV (29). The utility of the
vaccinia virus recombinant-expressed proteins as ELISA antigens
was confirmed after comparison with a previously validated in-
house ELISA (20) and with a widely used commercial kit (Genelabs
Diagnostics Inc., CA), to which they present a very good concor-
dance and an even better sensitivity and specificity. The in-house
test developed in this study allows 7,500 individual ELISA deter-
minations from the infection of 107 mammalian cells, making it a
relatively cheap and easy-to-apply tool for use in regions where
other alternatives are less available.
As mentioned above, until the recent description of HEV-sus-
ceptible cell culture (42, 43, 48, 49), the lack of an efficient, pro-
ductive cell culture for HEV has made unfeasible the use of live or
attenuated virus vaccines; thus, several recombinant proteins and
DNA candidates have been evaluated (1), some of which are in
clinical trials (41, 52, 53). However, no approved vaccine is com-
mercially available, and several aspects about its potential use re-
main to be elucidated, such as the duration of the response, its
usefulness against a fulminant course of the disease, and its cost-
effectiveness. Furthermore, an important aspect to address in an
HEV vaccine is its safety for use in pregnant women, because,
although still debated (30), HEV may account for higher rates of
mortality, spontaneous abortion, and neonatal death (33).
Since vaccinia virus has been widely used as a vaccine vector
(16, 32) and its potential for expressing HEV recombinant pro-
teins had been described in an early report (5), we analyzed the
potential of recombinant vaccinia viruses expressing HEV pro-
teins as immunogens in mice. Significantly, both recombinant
vaccinia viruses obtained (rVV-ORF2 and rVV-(1-111)-ORF2)
elicited high and long-lasting (up to 4 months) anti-HEV specific
antibody levels in mice, although those vaccinated with rVV-
ORF2 presented higher and earlier (after just two inoculations)
levels. These results are in concordance with those previously re-
ported for humans (52, 53) and mice (18). Differences between
the two immunogens could be due to their different intracellular
trafficking and glycosylation statuses, which may influence their
immunogenic capabilities.
As previously found using purified baculovirus-expressed re-
combinant proteins (18), the immunity acquired after infection of
pregnant mice with recombinant vaccine viruses was transmitted
to their offspring by both intrauterine and lactation routes, the
latter route being more efficient, as antibody titers raised by new-
borns nursed by vaccinated mothers were higher and longer-last-
ing than those raised by pups born to vaccinated mothers but
nursed by nonvaccinated ones. However, antibody titers were
lower and less lasting than those previously observed after vacci-
nation with baculovirus-expressed proteins (18). Although HEV
has recently been detected in rats with shedding of virus (21, 23,
37), andHEV experimental infection has been reportedwith nude
mice (15), HEV does not seem to infect immunocompetent mice
(26); therefore, the protective capacity of the immunological sta-
tus acquired by these animals after vaccination with the recombi-
nant vaccinia viruses was not evaluated.
In summary, our results show that vaccinia virus is a good system
for expression of HEV recombinant proteins that allows the study of
their intracellular localization and glycosylation patterns. The vac-
FIG 5 Levels of anti-HEV IgG antibodies over time in the offspring of mice vaccinated with rVV-ORF2 (A) or rVV-(1-111)-ORF2 (B). Anti-HEV IgG antibody
levels were measured in pups born to vaccinated mothers and raised by them (diamonds) or by unvaccinated foster mothers (triangles) and in pups born to
unvaccinated mothers and nursed by them (circles) or by vaccinated ones (squares). ELISAs were conducted as described previously (20). Results are expressed
as the average absorbance (A495) values. Standard deviations are shown by error bars.
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cinia virus-expressed proteins are also valuable diagnostic reagents
and vaccine candidates that deserve further study.
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